Literature DB >> 1808224

Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B.

M C Jung1, U Spengler, W Schraut, R Hoffmann, R Zachoval, J Eisenburg, D Eichenlaub, G Riethmüller, G Paumgartner, H W Ziegler-Heitbrock.   

Abstract

Since the hepatitis B virus is noncytopathic, it is generally believed that the individual specific immune response determines the course of infection. The lack of data about hepatitis B virus-specific T-cell reactions in acute infection led us to investigate the specific cellular immune response of infected individuals in terms of proliferation, and gamma-interferon and lymphotoxin production. Our results demonstrate that peripheral blood mononuclear cells (PBMNC) from patients with acute and chronic hepatitis B respond weakly to HBsAg. In contrast, patients with acute hepatitis show a vigorous response to the nucleocapsid antigen (HBcAg) in terms of proliferation and lymphokine production, while only few chronic virus carriers gave a proliferative response. Either of the antigens could activate lymphocytes to produce gamma-interferon and lymphotoxin, cytokines which may modulate antiviral immune response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808224     DOI: 10.1016/0168-8278(91)90074-l

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.

Authors:  Ji Chen; Yan Wang; Xue-Jie Wu; Jun Li; Feng-Qin Hou; Gui-Qiang Wang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 3.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

Review 4.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

Review 5.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

6.  Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.

Authors:  S Rossol; G Marinos; P Carucci; M V Singer; R Williams; N V Naoumov
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C.

Authors:  P M Yang; L H Hwang; M Y Lai; W L Huang; Y D Chu; W K Chi; B L Chiang; J H Kao; P J Chen; D S Chen
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

10.  T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.

Authors:  S Menne; J Maschke; M Lu; H Grosse-Wilde; M Roggendorf
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.